Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-sen University
This study is to assess the efficacy of IMRT combined with erlotinib compared with whole-brain radiotherapy for EGFR wild type non-small cell lung cancer with 4-10 brain metastases.
All patients recruited will be randomly assigned into two groups. Patients in experimental group will receive daily IMRT at 45 Gy in 15 fractions to brain metastases, combined with daily erlotinib of 150mg for three weeks. Patients in control group will receive daily whole-brain radiotherapy at 30 Gy in 10 fractions.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed NSCLC and wild type EGFR
4-10 brain metastases on high quality CT scanning or MRI.
No previous EGFR-TKI treatment.
No previous brain radiotherapy.
More than 4 weeks from last chemotherapy.
Expected Survival of at least 2 months.
KPS≥ 70
RTOG RPA performance status 0-1
Lab tests should meet these criteria: White blood cell count ≥3×10\^9 /L;Platelet count≥100×10\^9 /L;Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; Serum creatinine 1.5 times or less the ULN or creatinine clearance rate(CCR) greater than or equal to 60 ml/min.
